AzTrials
AzTrials

Androgenetic Alopecia (AGA)VENEZE-AGANCT07536100

VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia

A study testing Veneze peptide hair serum and Topical minoxidil in people with Androgenetic Alopecia (AGA), run by Institute of Dermatology, Thailand at 2 sites in Thailand.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Androgenetic Alopecia (AGA)
What is being tested?
Veneze peptide hair serum and Topical minoxidil
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
2 sitesThailand
Study dates
5 May 2026to 30 Nov 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female participants aged ≥18 years.
  • Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females.
  • Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire).
  • Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study.
  • Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit.
  • Able to attend all scheduled visits during the 24-week study period.

Who cannot join

  • Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia).
  • History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma.
  • Psychiatric disorders or other conditions that may affect participant safety or compliance.
  • Pregnant or breastfeeding women.
  • Hair and scalp-related exclusions:
  • Diffuse hair thinning involving the occipital area.
Show all 28Show fewer
  • Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis).
  • History of hair transplantation at any time or hair extensions within 6 months prior to screening.
  • Use of cosmetic products for hair loss concealment within 2 weeks prior to screening.
  • Use of light/laser therapy on the scalp within 3 months prior to screening.
  • Use of supplements related to hair growth (e.g., zinc, biotin) within 3 months prior to screening.
  • Use of hair products containing active ingredients (e.g., caffeine, peptides) within 3 months prior to screening.
  • Hair procedures such as mesotherapy or stem cell injection within 3 months prior to screening.
  • Medication-related exclusions:
  • Known hypersensitivity to study-related products or ingredients.
  • Use of dutasteride within 12 months prior to screening.
  • Use of systemic cytotoxic agents.
  • Use of systemic glucocorticoids within 3 months prior to screening (except inhaled or topical corticosteroids not applied to the scalp).
  • Use within 6 months prior to screening of:
  • Minoxidil (topical or oral)
  • Finasteride (topical or oral)
  • Anti-androgenic drugs (e.g., spironolactone, cyproterone acetate, flutamide, bicalutamide)
  • Prostaglandin analogs applied to the scalp
  • Estrogen or progesterone topical preparations
  • Tamoxifen
  • Drugs associated with hypertrichosis (e.g., cyclosporine, phenytoin)
  • Drugs associated with hair loss (e.g., valproic acid)
  • Participation in another clinical trial within 1 month prior to screening or during this study.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Chinmanat Lekhavat, MD, PhD contact

66023545222 ext. 1828

chinmanat@inderm.org

Suchanaree Laitrakul, MD contact

66023545222 ext. 1828

Thailand2 sites, 2 recruiting

  • Institute of dermatology

    Bangkok, Bangkok, 10400

    Suchanaree Laitrakul, MD, 66023545222, jahjaahh.scnr@gmail.com

    Recruiting

  • Institute of Dermatology

    Bangkok

    Recruiting

Other trials in Thailand

About this study

Official title: Effectiveness and Tolerability of VENEZE Peptide Factor Hair Serum for Pattern Hair Loss: A Randomized Double-blind Study

This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.

Read the detailed description

Androgenetic alopecia (AGA) is a common condition affecting both men and women and can significantly impact quality of life. Topical minoxidil is a widely used treatment; however, its effectiveness varies and it may cause local adverse effects in some patients. Peptide hair serums have emerged as a potential alternative, with proposed mechanisms including stimulation of hair follicle activity and promotion of hair growth.

This study aims to evaluate the efficacy and safety of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. The primary objective is to assess improvement in hair growth, including changes in hair density and hair thickness. Secondary objectives include evaluation of safety, tolerability, and patient-reported outcomes.

This is a randomized, double-blind, parallel-group study. Eligible participants with androgenetic alopecia will be randomly assigned to receive either the peptide-based hair serum or topical minoxidil. Treatments will be administered according to the study protocol over a defined study period.

Efficacy outcomes will include quantitative assessment of hair density and hair thickness. Safety will be evaluated through monitoring of adverse events and local tolerability.

Being tested
Veneze peptide hair serum, Topical minoxidil
Keywords
Androgenetic alopecia, Peptide hair serum, Minoxidil
Medical subject headings
Alopecia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Veneze peptide hair serumOther

    Also called Hair growth peptide serum

    Participants will apply the VENEZE peptide factor hair serum to the affected scalp areas twice daily for 24 weeks according to the study protocol

  • Topical minoxidilDrug

    Also called Topical Minoxidil 2% solution

    Topical minoxidil solution applied to the scalp according to the study protocol for the treatment of androgenetic alopecia.

Study groups in NCT07536100
Study groupRoleWhat they receive
VENEZE Peptide factor hair serumExperimentalParticipants in this arm will receive the VENEZE peptide factor hair serum applied topically to the scalp for 24 weeks.
Receives: Other: Veneze peptide hair serum
Topical 2% minoxidil solutionActive comparatorParticipants in this arm will receive 2% minoxidil solution applied topically to the scalp for 24 weeks.
Receives: Drug: Topical minoxidil

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in hair density from baseline

    Change from baseline in hair count within approximately 1 cm² target area at the vertex scalp, measured using standardized macrophotographic techniques at Weeks 12 and 24.

    Measured: 12 and 24 weeks

Secondary outcomes (5)

  1. Change in hair diameter and terminal hair count from baseline

    Change from baseline in hair diameter and the number of terminal hairs within approximately 1 cm² target area at the vertex scalp, measured using standardized macrophotographic techniques at Weeks 12 and 24.

    Measured: 12 and 24 weeks

  2. Investigator Global Aesthetic Improvement Scale

    Investigator assessment of treatment response using the Global Aesthetic Improvement Scale at the vertex and frontal scalp regions at baseline, week 12, and week 24.

    Measured: 12 and 24 weeks

  3. Change in androgenetic alopecia severity

    Change in AGA severity based on Norwood-Hamilton classification in males and Ludwig classification in females at baseline, week 12, and week 24.

    Measured: 12 and 24 weeks

  4. Patient Global Assessment of hair growth

    Change in patient-reported hair growth and satisfaction assessed using Patient Global Assessment (PGA) and Hair Growth Questionnaire scores at baseline, week 12, and week 24.

    Measured: 12 and 24 weeks

  5. Incidence of adverse events

    Incidence and severity of treatment-related adverse events recorded from baseline until the end of the study.

    Measured: 24 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Apr 2026
  2. Study start5 May 2026
  3. Primary completion30 Nov 2026 (estimated)
  4. Study completion30 Nov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be randomly assigned in a parallel-group design to receive either the peptide factor hair serum or 2% minoxidil solution for 24 weeks. Participants in each group will receive the assigned intervention throughout the study period. Efficacy outcomes and tolerability will be assessed and compared between the two groups.
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07536100
Sponsor's protocol ID
031/2568
Other IDs
IRB-IOD-031/2568
Acronym
VENEZE-AGA
Status last verified
May 2026
First submitted
11 Apr 2026
Last updated
13 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J, Binkowitz B, Gormley GJ. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):578-89. doi: 10.1016/s0190-9622(98)70007-6.

    PubMed 9777765

  • Lee YH, Choi HJ, Kim JY, Kim JE, Lee JH, Cho SH, Yun MY, An S, Song GY, Bae S. Ginsenoside Rg4 Enhances the Inductive Effects of Human Dermal Papilla Spheres on Hair Growth Via the AKT/GSK-3beta/beta-Catenin Signaling Pathway. J Microbiol Biotechnol. 2021 Jul 28;31(7):933-941. doi: 10.4014/jmb.2101.01032.

    PubMed 34099599

  • Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, Loy DE, Zhao T, Blatt HB, Stanton DC, Carrasco L, Ahluwalia G, Fischer SM, FitzGerald GA, Cotsarelis G. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012 Mar 21;4(126):126ra34. doi: 10.1126/scitranslmed.3003122.

    PubMed 22440736

  • Wadstein J, Thom E, Gadzhigoroeva A. Integral Roles of Specific Proteoglycans in Hair Growth and Hair Loss: Mechanisms behind the Bioactivity of Proteoglycan Replacement Therapy with Nourkrin(R) with Marilex(R) in Pattern Hair Loss and Telogen Effluvium. Dermatol Res Pract. 2020 May 5;2020:8125081. doi: 10.1155/2020/8125081. eCollection 2020.

    PubMed 32425997

  • Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic Alopecia: Therapy Update. Drugs. 2023 Jun;83(8):701-715. doi: 10.1007/s40265-023-01880-x. Epub 2023 May 11.

    PubMed 37166619

  • Bikash C. Topical Alternatives for Hair Loss: Beyond the Conventional. Int J Trichology. 2025 Jan-Feb;17(1):13-19. doi: 10.4103/ijt.ijt_8_23. Epub 2025 Jun 23.

    PubMed 40654553

  • Penha MA, Miot HA, Kasprzak M, Muller Ramos P. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol. 2024 Jun 1;160(6):600-605. doi: 10.1001/jamadermatol.2024.0284.

    PubMed 38598226

  • Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007 Nov;57(5):767-74. doi: 10.1016/j.jaad.2007.04.012. Epub 2007 Aug 29.

    PubMed 17761356

  • Truong VL, Jeong WS. Hair growth-promoting mechanisms of red ginseng through Wnt/β-catenin. Plants (Basel). 2021;10(10):2067.

  • Fang C, Chen Y, Zhao L, Huang Y, Li J, Xu Y, et al. Ginsenoside CK inhibits androgenetic alopecia by regulating dihydrotestosterone and Wnt/β-catenin in mice. Food Front. 2023;4(1):96-108.

  • Jeong G, Kim H, Ahn J, Yoon J, Lee J, Cho AR, et al. Ginsenoside Re prevents catagen by activating autophagy and Wnt/β-catenin in human dermal papilla cells. Int J Mol Sci. 2022;23(9):4885.

  • Zhang B, Zhang W, Luo J, He J, Zheng X, Zhu S, Rong B, Ai Y, Zhang L, He T. Effects of oleanolic acid on hair growth in mouse dorsal skin mediated via regulation of inflammatory cytokines. J Appl Biomed. 2023 Apr;21(1):48-57. doi: 10.32725/jab.2023.003. Epub 2023 Mar 27.

    PubMed 37016778

  • Huh S, Lee J, Jung E, Kim SC, Kang JI, Lee J, Kim YW, Sung YK, Kang HK, Park D. A cell-based system for screening hair growth-promoting agents. Arch Dermatol Res. 2009 Jun;301(5):381-5. doi: 10.1007/s00403-009-0931-0. Epub 2009 Mar 11.

    PubMed 19277688

  • Voiculescu VM, Raducan A, Popa LG, Cretu A, Draghici CC, Voinescu DC, et al. Comparative study of a topical and oral combination (Minoxicapil) in androgenetic alopecia: a 3-month clinical study. Cosmetics (Basel). 2025;12(4):152.

  • Thom E. Pregnancy and the hair growth cycle: anagen induction against hair growth disruption using Nourkrin(R) with Marilex(R) , a proteoglycan replacement therapy. J Cosmet Dermatol. 2017 Sep;16(3):421-427. doi: 10.1111/jocd.12286. Epub 2016 Sep 23.

    PubMed 27659896

Questions about this trial

What is this clinical trial studying?

A study testing Veneze peptide hair serum and Topical minoxidil in people with Androgenetic Alopecia (AGA), run by Institute of Dermatology, Thailand at 2 sites in Thailand.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Chinmanat Lekhavat, MD, PhD (66023545222 ext. 1828, chinmanat@inderm.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in hair density from baseline (time frame: 12 and 24 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07536100, which also lists 25 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in